[{"data":1,"prerenderedAt":224},["ShallowReactive",2],{"drug-viloxazine":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":51,"contraindications":103,"warnings":113,"renal":128,"monitoring":138,"interactions":139,"review":140,"examples":143,"atc":158,"iran":160,"links":167,"populations":184,"usApproval":219},"viloxazine",1,{"fa":7,"en":8},"ویلوکسازین","Viloxazine","nervous-system",{"fa":11,"en":12},"مهارکننده انتخابی بازجذب نوراپی‌نفرین (غیرمحرک)","Selective norepinephrine reuptake inhibitor (non-stimulant)",[14],{"name":15,"market":16},"Qelbree","US",[18,19,7],"qelbree","کلبری",[21,35,43],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":30,"refs":31},"er-100","capsule","oral","100 mg ER capsule",{"amount":27,"unit":28,"perUnit":23,"scored":29},100,"mg",false,[16],[32],{"source":33,"section":34},"fda-qelbree","3",{"id":36,"form":23,"route":24,"label":37,"concentration":38,"markets":40,"refs":41},"er-200","200 mg ER capsule",{"amount":39,"unit":28,"perUnit":23,"scored":29},200,[16],[42],{"source":33,"section":34},{"id":44,"form":23,"route":24,"label":45,"concentration":46,"markets":48,"refs":49},"er-150","150 mg ER capsule",{"amount":47,"unit":28,"perUnit":23,"scored":29},150,[16],[50],{"source":33,"section":34},[52,70,82],{"id":53,"disease":54,"label":55,"population":58,"type":64,"unit":28,"dose":65,"refs":67},"c6","adhd",{"fa":56,"en":57},"ADHD کودک ۶ تا ۱۱ سال — شروع ۱۰۰ mg یک بار؛ هفتگی ۱۰۰ mg تا حداکثر ۴۰۰ mg","ADHD, children 6–11 y — start 100 mg once daily; +100 mg weekly to max 400 mg",{"minAge":59,"maxAge":62},{"value":60,"unit":61},6,"year",{"value":63,"unit":61},12,"fixed",{"perDose":27,"perDoseMax":66,"dosesPerDay":5},400,[68],{"source":33,"section":69},"2.2",{"id":71,"disease":54,"label":72,"population":75,"type":64,"unit":28,"dose":79,"refs":80},"c12",{"fa":73,"en":74},"ADHD نوجوان ۱۲ تا ۱۷ سال — شروع ۲۰۰ mg؛ پس از ۱ هفته تا ۴۰۰ mg","ADHD, adolescents 12–17 y — start 200 mg; after 1 week up to 400 mg",{"minAge":76,"maxAge":77},{"value":63,"unit":61},{"value":78,"unit":61},18,{"perDose":39,"perDoseMax":66,"dosesPerDay":5},[81],{"source":33,"section":69},{"id":83,"disease":54,"label":84,"population":87,"type":64,"unit":28,"dose":89,"refs":91,"notes":93},"adult",{"fa":85,"en":86},"ADHD بزرگسال — شروع ۲۰۰ mg؛ هفتگی ۲۰۰ mg تا حداکثر ۶۰۰ mg","ADHD, adults — start 200 mg; +200 mg weekly to max 600 mg",{"minAge":88},{"value":78,"unit":61},{"perDose":39,"perDoseMax":90,"dosesPerDay":5},600,[92],{"source":33,"section":69},[94],{"text":95,"refs":98},{"fa":96,"en":97},"کپسول کامل بلعیده شود یا محتویات روی پوره سیب\u002Fپودینگ؛ نجوید. پیش از شروع ضربان و فشار و سابقه خودکشی\u002Fدوقطبی.","Swallow whole or sprinkle on applesauce\u002Fpudding; do not chew. Check HR\u002FBP and history of suicide\u002Fbipolar first.",[99,101],{"source":33,"section":100},"2.3",{"source":33,"section":102},"2.1",[104],{"id":105,"severity":106,"text":107,"refs":110},"ci","block",{"fa":108,"en":109},"MAOI همزمان یا ظرف ۱۴ روز (بحران فشار خون)؛ سوبستراهای حساس یا با دامنه باریک CYP1A2 (مثل تیزانیدین، تئوفیلین).","MAOIs concomitantly or within 14 days (hypertensive crisis); sensitive or narrow-range CYP1A2 substrates (e.g. tizanidine, theophylline).",[111],{"source":33,"section":112},"4",[114,121],{"text":115,"refs":118},{"fa":116,"en":117},"هشدار جعبه‌ای: افکار و رفتار خودکشی بیشتر از دارونما.","Boxed warning: higher rates of suicidal thoughts and behaviour than placebo.",[119],{"source":33,"section":120},"Boxed Warning",{"text":122,"refs":125},{"fa":123,"en":124},"افزایش فشار و ضربان؛ مانیا؛ خواب‌آلودگی.","Increased blood pressure and heart rate; mania; somnolence.",[126],{"source":33,"section":127},"5",[129],{"egfrBelow":130,"severity":131,"text":132,"refs":135},30,"warn",{"fa":133,"en":134},"eGFR زیر ۳۰: شروع ۱۰۰ mg، حداکثر ۲۰۰ mg.","eGFR \u003C30: start 100 mg, max 200 mg.",[136],{"source":33,"section":137},"2.4",[],[],{"status":141,"reviewer":142,"date":142},"unverified",null,[144,149,154],{"regimen":53,"formulation":22,"input":145,"expect":148},{"ageYears":146,"weightKg":147},8,25,{"perDose":27,"tabletsPerDoseRounded":5,"upperPerDose":66},{"regimen":71,"formulation":36,"input":150,"expect":153},{"ageYears":151,"weightKg":152},14,50,{"perDose":39,"tabletsPerDoseRounded":5,"upperPerDose":66},{"regimen":83,"formulation":36,"input":155,"expect":157},{"ageYears":130,"weightKg":156},70,{"perDose":39,"tabletsPerDoseRounded":5,"upperPerDose":90},[159],"N06AX09",{"status":161,"refs":162},"not-found",[163],{"source":164,"section":165,"url":166},"darooyab-generic","G-618\u002FViloxazine","https:\u002F\u002Fwww.darooyab.ir\u002FG-618\u002FViloxazine",[168,172,176,179,182],{"kind":169,"url":170,"label":171},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=211964","NDA211964",{"kind":173,"url":174,"label":175},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=aedf408d-0f84-418d-9416-7c39ddb0d29a","FDA Qelbree",{"kind":177,"url":178,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa621027.html",{"kind":180,"url":181,"label":159},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=N06AX09",{"kind":183,"url":166,"label":8},"darooyab",{"pregnancy":185,"lactation":194,"pediatric":203,"geriatric":211},{"level":186,"text":187,"quote":190,"refs":191},"avoid",{"fa":188,"en":189},"برچسب: می‌تواند به جنین آسیب بزند. در بارداری خطرناک است.","Label: can cause fetal harm. Dangerous in pregnancy.","Discontinue Qelbree when pregnancy is recognized unless the benefits of therapy outweigh the potential risk to the mother.",[192],{"source":33,"section":193},"8.1",{"level":195,"text":196,"quote":199,"refs":200},"caution",{"fa":197,"en":198},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary Available data from a lactation study in 15 women indicate that viloxazine and its metabolite, 5-HVLX-gluc, are present in breastmilk.",[201],{"source":33,"section":202},"8.2",{"level":195,"text":204,"quote":207,"refs":208},{"fa":205,"en":206},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","The safety and effectiveness of Qelbree in pediatric patients 6 to 17 years of age with ADHD have been established based on randomized, placebo-controlled studies in pediatric patients [see Adverse Reactions (6.1) and Clinical Studies (14) ] .",[209],{"source":33,"section":210},"8.4",{"level":195,"text":212,"quote":215,"refs":216},{"fa":213,"en":214},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","Clinical trials of Qelbree in the treatment of ADHD did not include sufficient numbers of patients aged 65 and older to determine whether or not they respond differently from younger patients.",[217],{"source":33,"section":218},"8.5",{"kind":220,"refs":221,"id":171},"NDA",[222],{"source":33,"section":223},"SPL approval \u002F marketing category",1792191572818]